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AbstrACt
Objective To characterise heart failure (HF) maintenance 
pharmacotherapy for children across Europe and 
investigate how angiotensin-converting enzyme inhibitors 
(ACE-I) are used in this setting.
Methods A Europe-wide web-based survey was 
conducted between January and May 2015 among 
European paediatricians dedicated to cardiology.
results Out of 200-eligible, 100 physicians representing 
100 hospitals in 27 European countries participated. All 
participants reported prescribing ACE-I to treat dilated 
cardiomyopathy-related HF and 97% in the context of 
congenital heart defects; 87% for single ventricle physiology. 
Twenty-six per cent avoid ACE-I in newborns. Captopril 
was most frequently selected as first-choice for newborns 
(73%) and infants and toddlers (66%) and enalapril for 
children (56%) and adolescents (58%). Reported starting and 
maintenance doses varied widely. Up to 72% of participants 
follow formal creatinine increase limits for decision-making 
when up-titrating; however, heterogeneity in the cut-off points 
selected existed. ACE-I formulations prescribed by 47% of 
participants are obtained from more than a single source. 
Regarding symptomatic HF maintenance therapy, 25 different 
initial drug combinations were reported, although 79% select 
a regimen that includes ACE-I and diuretic (thiazide and/or 
loop), 61% ACE-I and aldosterone antagonist; 44% start with 
beta-blocker, 52% use beta-blockers as an add-on drug. 
Of the 89 participants that prescribe pharmacotherapy to 
asymptomatic patients, 40% do not use ACE-I monotherapy or 
ACE-I-beta-blocker two-drug only combination.
Conclusions Despite some reluctance to use them in 
newborns, ACE-I seem key in paediatric HF treatment 
strategies. Use in single ventricle patients seems frequent, 
in apparent contradiction with current paediatric evidence. 
Disparate dosage criteria and potential formulation-
induced variability suggest significant differences may 
exist in the risk-benefit profile children are exposed to. No 
uniformity seems to exist in the drug regimens in use. The 
information collected provides relevant insight into real-life 
clinical practice and may facilitate research to identify the 
best therapeutic options for HF children.
IntrOduCtIOn
Despite its low incidence, paediatric heart 
failure (HF) is an important public health 
concern.1 It has been estimated that 
10%–33% of all paediatric cardiac admis-
sions are related to HF.2 3 Children whose 
hospitalisation is complicated by HF can have 
a >20-fold increase in the risk of death.4 
Congenital heart defects (CHD) are 
responsible for most cases diagnosed in 
developed countries, although the majority 
are resolved with surgery.2 Dilated cardio-
myopathies (DCM) are the main cause in 
patients with structurally normal hearts and 
account for 60% of paediatric cardiac trans-
plants in Europe.2 3 5 Interest in drug therapy 
has increased with the goal of keeping 
What is already known on this topic?
 ► While the benefits of pharmacotherapy in adult heart 
failure (HF) are well established, efficacy in paediat-
rics has yet to be confirmed.
 ► Therapeutic strategies are largely based on the ex-
trapolation of adult data and own experience. Little 
is known about drug treatment routines in everyday 
practice.
 ► Great uncertainty exists regarding optimal use of 
angiotensin-converting enzyme inhibitors (ACE-I) in 
HF children.
What this study hopes to add?
 ► ACE-I are key in paediatric HF therapy, even for chil-
dren with single ventricle physiology, in apparent 
contradiction with current paediatric evidence.
 ► Many physicians avoid using ACE-I in newborns and 
disparate usage criteria suggest significant differ-
ences may exist in the risk-benefit profile children 
are exposed to.
 ► No standardisation in dilated cardiomyopathy-re-
lated HF pharmacotherapy exists, and there appear 
to be marked deviations from conditions of use that 
current adult data support.
Protected by copyright.
 o
n
 M
ay 28, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000365 on 31 January 2019. Downloaded from 
2 Castro Díez C, et al. BMJ Paediatrics Open 2019;3:e000365. doi:10.1136/bmjpo-2018-000365
Open access
patients stable until cardiac transplant or surgery can be 
performed and/or to delay or avoid the need.6
Beneficial effects of pharmacotherapy for adult HF 
are well established. Different neurohumoral antago-
nists have shown to impact the disease prognosis, among 
which angiotensin-converting enzyme inhibitors (ACE-I) 
are the only drugs recommended by both European and 
American adults HF guidelines for all patients.7 8 However, 
the efficacy of these medicines in children has yet to be 
confirmed. Evidence in paediatrics comes mainly from 
heterogeneous observational and small experimental 
studies, while the only two published large randomised 
controlled trials (RCT) failed to prove benefit.9 10 In the 
absence of conclusive data, paediatric therapeutic strat-
egies are largely supported by adults’ data extrapolation 
and own expertise.11 12 Commonly used drug treatment 
routines are mostly unknown.
ACE-I use may have become extensive in paediatric 
HF; however, unlike in adults, limited practical guidance 
exists to support the decision-making process associated 
with their clinical use.11 13 Off-label prescribing, with its 
associated challenges and risks,14 is often needed. Little 
is known about how clinicians overcome this knowledge 
gap in everyday practice.
We conducted this study with the aims of characterising 
HF maintenance pharmacotherapy practices for children 
across Europe and enhancing understanding of the appli-
cation of ACE-I in this condition. This might serve as a 
basis to determine priorities and facilitate future discus-
sion and research to optimise the medical care provided 
to the paediatric HF population.
MethOds
Overall study design
A web-based survey type study design was selected to 
provide the best opportunity to collect information 
from a wide range of participants where resources of 
time, staff and budget were limited. Previous relevant 
surveys were reviewed and recommendations published 
in survey best practice guidelines followed.15–18 Thirteen 
experts supported the various steps of the study design. 
The process for the survey and survey instrument design 
and its distribution to participants is described in online 
supplementary figure S1.
Questionnaire topics were selected from the results 
of a literature review and expert group discussions. 
The survey was peer reviewed and pretested and pilot-
tested by members of the expert panel and reliability 
and validity were assessed with positive results.15 16 The 
resulting questionnaire (online supplementary figure 
S2) explored usage patterns of ACE-I and drug therapy 
for DCM-related HF. Demographic questions about 
participants were also included.
study participants
The target population was physicians providing paediatric 
cardiology care in hospitals across Europe (48 countries 
targeted), with the aim to have representation of each 
hospital. Since no official registries exist, a non-proba-
bility sampling design was deemed acceptable.15 Centres 
and physicians’ contact data were identified through 
European and national paediatric cardiology association 
websites and presidents, hospital and cardiology confer-
ences websites and LENA (https://www. lena- med. eu) 
consortium partners.
survey administration, data collection and statistical analysis
An invitation email, containing an individualised survey 
participation link, was sent to each clinician. Email and 
postal reminders were sent to non-respondents (online 
supplementary figure S1).
Data were collected between January and May 2015. To 
minimise errors during data processing, data extraction 
from the EvaSys web-survey platform and preparation of 
ready-to-analyse data was conducted by two researchers 
independently, and results were checked for consistency.
For the analysis of reported ACE-I doses in use, where 
a participant entered a starting dose range, the lower 
limit was considered. Where a participant entered a 
maintenance dose range, the median value was recorded 
for analysis. Answers were excluded from analysis if: (1) 
the exact requested information (starting dose in mg/
kg/dose and maintenance dose in mg/kg/day) was not 
provided, (2) target dose reported was smaller than 
starting dose or (3) the dose entered was considered not 
to be compatible with current knowledge (≥10 times the 
larger doses reported in literature for children and/or 
adults).
Data analysis was performed using R V.3.2.1 and 
R-Studio V.099.465. Descriptive statistics were used. Asso-
ciation between variables was statistically tested using 
Fisher’s exact test. Charts presented were created in 
Excel V.16.10.
ethics approval
This study was conducted in compliance with the EU 
Data Protection Directive 95/46/EC and approved by 
the Heinrich-Heine-University Düsseldorf Institutional 
Ethics Committee and Data Protection Officer.
Patient and public involvement
No patients were involved.
results
Physicians representing 204 different hospitals in 39 
countries were invited to participate, of whom 200 were 
considered for the analysis. The survey achieved an 
overall response rate of 50% (100/200). Physicians from 
27 different countries participated (figure 1). Most of 
them were working in a paediatric cardiology unit (91%) 
with over 5 years work experience in this field (96%) 
(online supplementary table S1). Seventy per cent of 
participants considered pharmacotherapy to have an 
impact of between 6 and 8 points out of 10 on the course 
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of the disease; 82% selected scores ≥6 (online supple-
mentary figure S3).
ACe-I use in hF according to aetiology: dCM and Chd
All participants reported using ACE-I therapy when DCM 
is the underlying cause of HF and 97% in the context 
of CHD (online supplementary table S2). Figure 2 shows 
the responses of the latter 97 participants on ACE-I use 
within four types of CHD according to HF symptomatic 
state. Eighty per cent reported using ACE-I in patients 
with CHD after heart surgery, the majority (64%) for a 
period of between 1 and 6 months (online supplemen-
tary table S3).
ACe-I use by age group
ACE-I were reported to be used for the management 
of HF in all paediatric age groups, although 26% avoid 
using them in the newborn population (figure 3). No 
statistically significant association was found between the 
prescription of ACE-I to newborns and different variables 
related to the physicians or their working environment 
(online supplementary table S4).
Figure 1 Survey participation/response rate by country and region. Hospitals were eligible if contact data of one clinician 
dedicated to the field of paediatric cardiology were available. We were able to find contact data of physicians from 204 different 
hospitals in 39 European countries. Four were excluded from analysis: one physician contacted expressed his wish not to 
participate, one did not feel able to participate because of limited experience, one was retired and one returned the completed 
questionnaire after the pre-established deadline. If more than one physician in a hospital answered, only the first questionnaire 
received was taken into consideration for analysis. Response rate was calculated as the number of different hospitals from 
which at least one physician submitted a completed or partially completed questionnaire divided by the number of different 
hospitals from which a physician was sent the invitation with questionnaire link. Criteria of the United Nations statistical division 
for Europe41 were followed for the classification of countries by European region. Four of the countries referred to are not 
considered as being European in this classification. Armenia and Azerbaijan were assigned here to Eastern Europe, Cyprus and 
Turkey to Southern Europe. 
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Figure 2 ACE-I use for the management of congenital heart defects. This question was applicable to 97 participants (n total 
for percentage calculation). Most of those 97 participants agreed on the usefulness of the therapy with ACE-I in patients with 
LRS lesions (80/97=82%) single ventricle lesions (84/97=87%) and/or valve regurgitation (92/97=95%). A marked division of 
opinions existed among the physicians asked with regard to pressure overloading lesions (44/97=45% yes vs 51% no). Twelve 
participants reported using ACE-I for other CHD (mainly systemic right ventricle, Marfan syndrome, postsurgical correction of 
aortic coarctation, complex CHD). ACE-I, angiotensin-converting enzyme inhibitors; CHD, congenital heart defect; LRS, left-to-
right shunt. 
Figure 3 First-choice ACE-I by age group. Age groups were defined according to age classification for paediatric patients 
proposed by the EMA.42 72% of the participants reported prescribing ACE-I in all age groups. ACE-I, angiotensin-converting 
enzyme inhibitor.
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Figure 4 Starting dose (mg/kg/dose) and maintenance/target daily dose (mg(kg/day) in use reported by survey participants 
for captopril and enalapril by age group. Opacity of each point is proportional to the number of participants that entered that 
dose. Diamonds (◊) indicate median values. Thick horizontal lines indicate ranges of paediatric dosage recommendations 
that have been published.11 13 27 Detailed results corresponding to these figures are provided in online supplementary tables 
S8 and S9. Age groups were defined as follows: newborns 0–27 days, infants and toddlers 28 days to 23 months, children 
2–11 years and adolescents 12–18 years.42 Mean of starting doses reported for captopril was: 0.22 mg/kg/dose for newborns, 
0.26 mg/kg/dose for infants and toddlers, 0.33 mg/kg/dose for children and 0.18 mg/kg/dose for adolescents. The mean of 
enalapril reported staring doses was: 0.06 mg/kg/dose for newborns and infants and toddlers, 0.08 mg/kg/dose for children 
and 0.09 mg/kg/dose for adolescents. SD values are provided in online supplementary table S6. The reported captopril mean 
maintenance doses were 1.58, 1.99, 2.30 and 1.75 mg/kg/day for each age group, respectively, in order of increasing age. 
Mean of maintenance doses reported for enalapril was 0.27 mg/kg/day for newborns and 0.41, 0.42 and 0.43 mg/kg/day for 
infants and toddlers, children and adolescents, respectively. SD values are provided in online supplementary table S7.
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Of those participants using ACE-I within each age 
group, the majority selected captopril as the ACE-I of 
choice for newborns (73%) and infants and toddlers 
(66%), while enalapril was the most selected for children 
(56%) and adolescents (58%) (figure 3). Participants’ 
main rationale for this choice is shown in online supple-
mentary table S5.
dosage of first-choice ACe-I
A wide range of starting (mg/kg/dose) and mainte-
nance doses (mg/kg/day) were reported for each ACE-I 
and age group in virtually all cases. Results for the most 
commonly prescribed ACE-I, captopril and enalapril, are 
presented in figure 4. Summary statistics of all results 
is provided in online supplementary tables S6 and S7. 
Dosing frequencies reported for maintenance doses 
for each ACE-I within each age group are presented in 
figure 5.
Division of opinions existed among the physicians 
surveyed on the best criterion that should be followed 
to establish the optimal ACE-I maintenance dose. In 
response to the question ‘Do you increase the dose 
of ACE-I to your target, although patient has already 
improved with a lower dose?’ Forty-five per cent of 
the participants answered ‘No’, 42% ‘Yes’ and 13% 
‘Sometimes’.
ACe-I effectiveness and toxicity assessment
All participants reported that they consider changes in 
signs and symptoms to assess the effectiveness of the ACE-I 
therapy. Ninety per cent rely on echocardiographic or 
radiographic parameters. Half of the physicians consider 
the level of natriuretic peptide and, similarly, 54% make 
use of clinical scores, 55% parents’ perception and 
55% the need for anticongestive medication. Only 15% 
reported applying quality of life scores.
In figure 6, we display responses of participants on their 
attitude towards deterioration of renal function under 
ACE-I therapy in terms of serum creatinine increase. 
Regarding hypotension onset, 81% of participants 
reported basing the decision of stopping increasing the 
ACE-I dose on a defined criterion, while only 29% apply a 
Figure 5 Dosing frequency of ACE-I maintenance dose reported for ACE-I of choice selected for each age group. Age groups 
were defined as follows: newborns 0–27 days, infants and toddlers 28 days to 23 months, children 2–11 years and adolescents 
12–18 years.42 Captopril appeared to be most commonly prescribed three times per day and enalapril two times a day in all 
paediatric age groups except for adolescents. In this age group, the prevalence of prescribing enalapril once a day was similar 
to two times a day prescribing. Similarly, the percentage of clinicians reporting captopril administration two times and three 
times a day for adolescents was as high. Participants who reported using lisinopril, perindopril, ramipril and/or trandolapril 
prescribe these ACE-Is in single daily doses in virtually all cases. Answer option ‘4 times per day’ was also provided, but this 
was not selected in any case. One of the 30 participants that reported using captopril for children did not specify any dosing 
frequency. ACE-I, angiotensin-converting enzyme inhibitor.
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criterion for therapy withdrawal. Most of them (77%) use 
absolute blood pressure cut-off points according to age.
ACe-I formulations
Forty-seven per cent of the participants reported using 
liquid dosage forms, 44% capsules and 27% powder, when 
the adults’ formulation is not suitable for a paediatric 
patient. Most of the physicians (77%) selected a single 
type of formulation, but 47% indicated that they relied 
on more than one source (hospital pharmacy, commu-
nity pharmacy, prepared by parents and/or others) to 
supply these formulations (online supplementary tables 
S10 and S11).
drug regimens for the management of hF due to dCM—
symptomatic patients
Table 1 provides participants’ responses to questions 
regarding drugs introduced as initial therapy for patients 
with DCM HF who are not dependent on inotropic drugs, 
and medication introduced as add-on therapy where 
patients remain symptomatic.
Twenty-five different drug combinations were reported 
to be used for initial therapy (table 2). Seventy-nine 
per cent start treatment with a drug regimen that includes 
an ACE-I and a thiazide and/or loop diuretic, while 61% 
initiate treatment with a combination that includes an 
ACE-I and an aldosterone antagonist and 53% combine 
all three. Forty-four per cent of participants start with 
beta-blocker, while 52% use them as add-on therapy 
for patients that remain symptomatic. Fifty-four partici-
pants use cardiac glycosides, most of them (39) as add-on 
therapy.
drug regimens for the management of hF due to dCM—
asymptomatic patients
Most of the participants (89%) consider pharmacolog-
ical therapy for asymptomatic patients with DCM. Nine-
ty-one per cent of them reported using ACE-I in this situ-
ation, with 29% as monotherapy. Twenty-nine per cent 
prescribe a two-drug only combination of ACE-I and 
beta-blocker. Detailed information is displayed in online 
supplementary tables S12 and S13.
dIsCussIOn
This survey offers an overview of drug prescribing 
patterns for paediatric HF management across Europe 
and the criteria applied when using ACE-I to treat this 
condition. Eighty-two per cent of the participating physi-
cians consider pharmacotherapy to have an impact ≥6 
Figure 6 Attitude towards deterioration of renal function in terms of baseline serum creatinine level increase in the context 
of ACE-I therapy. The thresholds of baseline serum creatinine levels increase were based on the KDIGO proposed staging 
for acute kidney injury.43 Participants were requested to select the answer option that most reflected their practice. When 
considering deterioration of renal function in patients under ACE-I therapy, 25% of the participants claimed not to base 
treatment decisions on any formal cut-off value. A rise of 1.5 to 1.9-times in serum creatinine level was the most frequently 
selected limit as the criterion to stop increasing dose by those that reported being guided by formal limits (61%, 44 out of 72), 
while an increase of 2.0–2.9 times creatinine was the most frequently selected option for therapy withdrawal (51%, 36 out of 
71). ACE-I, angiotensin-converting enzyme inhibitor.
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out of 10 points on the course of the disease, suggesting 
positive outcomes are being made in everyday practice.
ACe-I use in paediatric hF: when?
All survey participants agreed on their appropriateness 
for children with HF when DCM is the underlying cause. 
ACE-I-related benefits in humoral and haemodynamic 
parameters have been documented in DCM children, 
but, unlike in adults, only few improvements in clinical 
terms.19–22 However, it is widely accepted that ‘DCM is 
the cause of paediatric HF that is most similar to that 
in adults’23 and thus, the assumption that benefits of 
the same drug therapy also apply. Paediatric guidelines 
recommend using ACE-I in children with symptomatic 
and asymptomatic ventricular dysfunction.11 12 Our 
results suggest this is indeed an extended practice across 
Europe; all participants reported prescribing ACE-I for 
symptomatic patients with DCM, 96% as starting therapy. 
Of the physicians that treat asymptomatic patients, 91% 
rely on ACE-I.
Virtually all physicians (97%) claimed to use ACE-I in 
the context of CHD. These children represent a highly 
heterogeneous group where the origin of HF is very 
often not limited to ventricular dysfunction,1 with the 
extrapolation of adult data becoming more complex. 
Our results suggest that European paediatricians believe 
that ACE-I plays an important role in the therapy of valve 
regurgitation, left-to-right shunt lesions, single ventricle 
physiology and in the postsurgical setting, for which 
80% claimed to prescribe them. Regarding valve regur-
gitation, haemodynamic benefits have been described 
in small experimental studies that included only asymp-
tomatic children.24 25 However, most of the participants 
(77) considered symptomatic patients to also benefit 
from therapy. The 87% who reported prescribing ACE-I 
for single ventricle physiology patients is perhaps our 
most surprising finding. This appears to contrast with the 
conclusions of the authors of the only published large 
RCT in this patient group whose results did ‘not support 
the routine use of enalapril’.9 A US Pediatric Heart 
Network survey revealed that, even though a significant 
change in clinical practice seemed to have occurred, 22% 
of physicians consulted were not familiar with the results 
of this study and 28% of those who were aware did not 
change decisions accordingly, mainly due to disagree-
ment with study design and interpretation of findings.26 
These might have been also the reasons behind our study 
participants’ responses. Overall, our observations suggest 
reliance on evidence in adults has a strong influence 
regarding decisions on ACE-I use in children with CHD.
Twenty-six per cent of physicians avoid using ACE-I 
in neonates. This is most likely due to potential variable 
responses to ACE-I in this age group together with low 
age and weight being recognised as key risk factors for 
renal failure in children on ACE-I.25 27 28 Our finding 
highlights the need for guidance to allow optimal use of 
this drug class in the youngest population.
ACe-I in paediatric hF: how?
Our results suggest that captopril is the ACE-I of choice 
for newborns (73%) and infants and toddlers (66%), 
with enalapril for children (56%) and adolescents (58%). 
Long-acting ACE-I represent 30% of the first-choices 
reported for adolescents.
The range of starting and maintenance ACE-I doses 
reported was wide. Effective paediatric dosages have not 
yet been established and doses used in reported publica-
tions are varied.25 Predominantly based on adults’ data, 
starting with 0.05–0.1 mg/kg/dose and 0.1–0.2 mg/kg/
dose for enalapril and captopril, respectively, has been 
Table 1 Report on drug use in maintenance therapy of symptomatic heart failure related to dilated cardiomyopathy
Initial therapy Add-on therapy
Participants that 
gave duplicate 
answers Overall total
Drug class n/total % n/total % n n/total %
ACE-I 96/100 96 9/100 9 5 100/100 100
Angiotensin receptor blocker 2/100 2 8/100 8 1 9/100 9
Beta-blocker 44/100 44 52/100 52 5 91/100 91
Loop diuretic 76/100 76 19/100 19 3 92/100 92
Thiazide diuretic 14/100 14 21/100 21 2 33/100 33
Aldosterone antagonist 65/100 65 27/100 27 4 88/100 88
Cardiac glycoside 16/100 16 39/100 39 1 54/100 54
Other 2/100 2 6/100 6 0 – – 
The results corresponding to two multiple-choice questions are presented, one referring to initial therapy and one referring to add-on therapy 
prescribed for patients that remain symptomatic despite initial therapy. Some of the participants gave a duplicate answer, as they selected 
the same drug class in both questions (column ‘Participants that gave a duplicate answer’). The total number of physicians that reported 
prescribing each drug class for the therapy of DCM-related symptomatic heart failure is presented under column ‘overall total’.
Drugs reported under ‘other’ were acetylsalicylic acid and ivabradine for initial therapy and ivabradine and intravenous inotropics for add-on 
therapy.
ACE-I, angiotensin-converting enzyme inhibitors; DCM, dilated cardiomyopathy.
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recommended.11 13 27 Participants’ reports are largely in 
line with or above these ranges. The British National 
Formulary for children recommends starting with 
0.01 mg/kg enalapril in neonates,27 but our data suggest 
this conservative approach is not routine practice. In 
contrast, reported maintenance doses tend to be below 
recommendations (enalapril 0.5–1 mg/kg/day; capto-
pril 0.5–2 mg/kg/day for neonates, 2.4–6 mg/kg/day for 
older age groups) except for captopril in newborns.11 13 27 
Evidence in adults indicates an apparent advantage of 
high versus low doses in terms of mortality and hospi-
talisations reduction.29 Therefore, our results suggest 
paediatric patients might be frequently receiving poten-
tially suboptimal doses. Perhaps poor tolerance hinders 
achieving high ACE-I doses in HF children,9 but it is also 
possible that this is linked to the criterion followed to 
establish the optimal maintenance dose; 45% of partic-
ipants reported they would stop uptitration once patient 
improvement had been observed. In adults, it appears 
the mechanisms that cause ACE-I long-term benefits are 
not relevant to symptom control,30 and hence, aiming 
towards the target doses selected in pivotal clinical trials, 
or failing this, towards the highest tolerated dose, is 
recommended.7 Considering an analogous approach for 
Table 2 Drug regimens used as the initial maintenance therapy of symptomatic heart failure related to dilated 
cardiomyopathy
Drug combinations n/total %
Single-drug regimen
  ACE-I 5/100 5
Two-drug regimen
  ACE-I+Loop diuretic 12/100 12
  ACE-I+Aldosterone antagonist 1/100 1
  ACE-I+Beta-blocker 4/100 4
  ACE-I+Thiazide diuretic 1/100 1
  Aldosterone antagonist+Loop diuretic 2/100 2
Three-drug regimen
  ACE-I+Aldosterone antagonist+Loop diuretic 20/100 20
  ACE-I+Aldosterone antagonist+Beta-blocker 4/100 4
  ACE-I+Aldosterone antagonist+Thiazide diuretic 1/100 1
  ACE-I+Aldosterone antagonist+Cardiac glycoside 3/100 3
  ACE-I+Beta blocker+Loop diuretic 7/100 7
  ACE-I+Beta blocker+Thiazide diuretic 1/100 1
  ACE-I+Cardiac glycoside+Loop diuretic 4/100 4
  Aldosterone antagonist+Loop diuretic+Thiazide 1/100 1
Four-drug regimen
  ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic 14/100 14
  ACE-I+Aldosterone antagonist+Beta blocker+Thiazide diuretic 4/100 4
  ACE-I+Aldosterone antagonist+Loop diuretic+Cardiac glycoside 3/100 3
  ACE-I+Aldosterone antagonist+Loop diuretic+Thiazide diuretic 1/100 1
  ACE-I+ARB +  Loop diuretic+Cardiac glycoside 1/100 1
  Aldosterone antagonist+Beta blocker+Cardiac glycoside+Loop diuretic 1/100 1
Five-drug regimen
  ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic+Thiazide diuretic 4/100 4
  ACE-I+Aldosterone antagonist+Beta blocker+Cardiac glycoside+Loop diuretic 3/100 3
  ACE-I+Aldosterone antagonist+Cardiac glycoside+Loop diuretic+Acetylsalicylic acid 1/100 1
  ACE-I+Aldosterone antagonist+Beta blocker+Loop diuretic+Ivabradine 1/100 1
Six-drug regimen
  ACE-I+Aldosterone antagonist+ARB +  Beta-blocker+Loop diuretic+Thiazide diuretic 1/100 1
Most of the participants start with 2 (20%), 3 (41%) or 4 (24%) drugs in combination. One third of participants (34%) reported starting with 
a drug combination that includes four or more drugs. Figures for the three drug regimens that were reported most frequently have been 
emphasised in bold.
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
Protected by copyright.
 o
n
 M
ay 28, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000365 on 31 January 2019. Downloaded from 
10 Castro Díez C, et al. BMJ Paediatrics Open 2019;3:e000365. doi:10.1136/bmjpo-2018-000365
Open access
children would seem reasonable, but systematic data are 
needed to elucidate the best strategy.
The apparent lack of consistent and well-defined 
endpoints in reported paediatric HF studies represents 
a major obstacle in determining optimal dosing strategy. 
Our results may outline some opportunities for prog-
ress. Ninety per cent of participants reported using 
cardiac imaging to evaluate ACE-I therapy effectiveness, 
suggesting that standardising relevant measurements and 
quantification methods might bring substantial benefits. 
Only 54% of respondents translate clinical observations 
into HF scores. This may be another area of improvement 
since despite limitations, such scales are a means of facil-
itating communication in daily practice and research.31 
Harmonising criteria to assess response to ACE-I therapy 
would enable the interpretation of published research 
and data sharing to evaluate therapy outcomes.
Similarly, disparity appeared to exist regarding the eval-
uation of ACE-I related adverse events. Deterioration of 
renal function and hypotension are those most commonly 
reported in children with HF, however, clear and consis-
tent definitions, and standardised decision criteria for 
actions to be taken when these occur are lacking.32 No 
uniformity existed in the thresholds considered by partic-
ipants to decide when to stop uptitration and/or with-
draw ACE-I therapy if renal function deterioration was 
observed. Only 29% had a fixed criterion to withdraw 
therapy if hypotension occurs. Even though this topic is 
complex, and no clear relationship has been established 
between dose level and risk of adverse events,32 our results 
suggest it is likely that some patients are exposed to 
higher risks, while others might be deprived of potential 
benefits due to premature dose reduction or withdrawal.
A further challenge regarding dosing of ACE-I in paedi-
atrics is the lack of authorised age-appropriate formu-
lations licensed for use in paediatric HF throughout 
Europe. Our results imply that many patients could 
potentially be exposed to significant formulation-induced 
variability in dose since 47% of the respondents indicated 
that the ACE-I formulations they prescribe are provided 
by more than a single source, and 23% prescribe more 
than a single type of formulation. Studies in the UK and 
Ireland documented that ACE-I preparations used to 
overcome the lack of licensed medicines are heteroge-
neous and a variety of them with no proven bioequiva-
lence are used interchangeably to treat HF children,33 34 
which can lead to uncertainty in the dose level achieved. 
This may also be relevant to the interpretation, compara-
bility and validity of ACE-I safety and efficacy published 
data, where information on the drug formulation and its 
administration is often omitted.
therapeutic schemes for hF due to dCM
We focused on DCM-related HF to define a more homo-
geneous scenario. The 25 different drug combinations 
reported for initial therapy reflect a lack of uniformity. 
However, 79% of participants agreed on starting with a 
drug regimen that combines an ACE-I with loop and/or 
thiazide diuretic, in line with current paediatric guide-
lines.11 12 In contrast, a large percentage of the partici-
pants have a criterion on aldosterone antagonists use 
that differs from published recommendations, as 65% 
include them as starting therapy. Evidence in adults (no 
paediatric data exist) supports the use of low-dose aldos-
terone antagonists in patients that remain symptomatic 
despite initial therapy, to reduce mortality and hospital-
isations.7 8 We can speculate that, rather than for their 
potential to influence prognosis, aldosterone antagonists 
are often introduced in paediatrics for their potassium 
sparing diuretic effect. However, it should be noted that 
Terano et al35 found concomitant use of spironolactone 
to be an independent risk factor for acute kidney injury 
in HF children on ACE-I. Regarding beta-blockers, 91% 
of participants prescribe them to treat symptomatic 
patients, but 52% reserve them for add-on therapy. In 
the only published large RCT on beta-blockers in paedi-
atric HF, carvedilol did not significantly improve clin-
ical outcomes.10 However, a recent Cochrane review 
concluded that despite insufficient evidence, existing 
data suggest that children with congestive HF might 
benefit from them.36 Paediatric guideline recommenda-
tions on beta-blocker use are less stringent.11 12 Our results 
seem to reflect a cautious attitude. Fifty-four participants 
reported using cardiac glycosides. Digoxin has histor-
ically been the mainstay of HF therapy, but no system-
atic data in children with structurally normal hearts have 
been published, and agreement currently exists on their 
only limited role in adults. Our results suggest there is 
still wide perception that they are of benefit.
Drug therapy for the management of asymptom-
atic DCM children also seems widespread (89%). 
Since 83%–90% of children affected with DCM will 
develop HF,37 38 interventions with the aim of delaying/
preventing the worsening of the condition appears to 
be a particularly relevant topic. Universal agreement 
exists that all adults with asymptomatic left ventricular 
dysfunction should receive an ACE-I.7 8 Adding a beta-
blocker concomitantly has proven beneficial, although 
advantages in adults without a history of myocardial 
infarction are less clear.7 8 Twenty-nine per cent of these 
paediatricians reported prescribing ACE-I monotherapy 
in this scenario and 29% a two-drug only combination of 
ACE-I and beta-blocker. While this might be justified by 
extrapolation from adults, the remaining 42% of physi-
cians decide on a drug regimen that appears not to be 
supported by any evidence.
limitations
Our results are constrained by the reliance on self-re-
ported clinicians’ practice.39 We were not able to enrol 
a statistically representative sample and responses of an 
individual physician cannot be assumed to be consistent 
with practice of others from the same institution. Thus, 
our findings may not be extrapolated to standard Euro-
pean clinical practice. However, population characteristics 
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indicate that a comprehensive picture of the current state 
of HF treatment routines has been provided.
Several factors favour the quality of our study. Survey 
instrument development included the recruitment of 
a supporting expert panel, pretesting and pilot-testing, 
reliability and validity testing with positive results, and 
a statistical analysis manual was elaborated for the 
processing and analysis of data.15 16
Conclusion
Despite some reluctance to their use in newborns, large 
reliance on ACE-I therapy for HF children seems to exist 
among European paediatricians. The apparent discrep-
ancy between our observations and the conclusions of 
the Infant Single Ventricle trial is remarkable.9 Heter-
ogeneity in ACE-I usage criteria and potential formula-
tion-induced variability suggest that significant differ-
ences may exist in the risk-benefit profile children are 
exposed to, clearly showing that the collation and evalu-
ation of systematic data should be a priority. Meanwhile, 
utilisation of best knowledge available should be maxim-
ised to seek agreement and reduce unjustified variability.
No uniformity in the drug combinations selected for 
DCM-related HF therapy exists. We observed common 
trends consistent with adults’ evidence as well as marked 
deviations: frequent use of aldosterone antagonists as 
initial therapy and observations regarding asymptomatic 
patients.
Established prescribing practices play a critical role 
in the viability of further research.40 The information 
collected provides relevant insight into real-life clinical 
practice, and it might serve to highlight areas of contro-
versy, provide a basis to design research and policies 
and stimulate scientific collaboration to achieve the 
common goal of effective and safe pharmacotherapy in 
HF children.
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